on Vitruvia Medical AG (isin : CH0461931419)
Vitruvia Medical AG Reports First Profit in 2025
Vitruvia Medical AG, based in Anglikon, disclosed its annual results for the year ending December 31, 2025. The company posted its first after-tax profit of CHF 308,670.73, contrasting with a loss of CHF 173,775.93 in the previous year. This marks a significant financial turnaround for the company.
The subsidiary, LT Technologies GmbH & Co. KG, contributed notably to this success, achieving a revenue increase of 26%, from EUR 2,016,279 to EUR 2,540,929. On a consolidated basis, EBITA saw a substantial rise from EUR 178,398 to EUR 277,215, a remarkable 55% improvement.
The investment in LT Technologies surpassed expectations, meeting and exceeding set targets for 2025. Looking forward to 2026, Vitruvia anticipates further growth in LT Technologies’ revenue and profit metrics.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Vitruvia Medical AG news